Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | Original Article | Ausgabe 2/2015

European Surgery 2/2015

The effects of sulforaphane in the rat model of experimental intestinal ischemia reperfusion

European Surgery > Ausgabe 2/2015
MD T. Talih, MD Assist. Prof. E. Arslan, MD Prof. E. Sozuer, MD Prof. A. Akcan, MD Assoc. Prof. H. Akyıldız, MD Assist. Prof. M. Akyüz, MD Prof. C. Yazıcı



The aim of this study is to investigate the effects of sulforaphane (SFN), which has been shown to protect such organs as the brain, kidneys, liver, and heart against the injury caused by ischemia reperfusion (I-R), on the reperfusion injury in the experimental intestinal I-R model.

Material and method

The study employed 30 Wistar albino rats, and there were three groups: the control group (n = 10), I-R group (n = 10), and SFN + I-R group (n = 10). The rats in the control group were sacrificed after a 3-h follow-up subsequent to the laparotomy. The I-R group was subjected to an hour of ischemia and 2 h of reperfusion afterward. The SFN + I-R group was administered a dose of 3 mg/kg SFN intraperitoneally. The rats were sacrificed after the ileum resection for measurement of tissue malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) activity and histopathological analysis.


The I-R and SFN + I-R groups were histopathologically shown to have similar cell injuries. In the SFN + I-R group, the increase in GSH-Px activity was higher than SOD activity and both of the increases were statistically significant compared with the control group (p < 0.001). The SFN application did not yield a significant difference in the tissue MDA level compared with the control group.


The effect of SFN use on the I-R injury in the intestine did not show an apparent effect histopathologically, although there were statistically significant differences in biochemical parameters.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2015

European Surgery 2/2015 Zur Ausgabe